PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
about
Akt and mTOR in B Cell Activation and DifferentiationDiffuse large B-cell lymphoma: current strategies and future directionsTargeting Btk/Etk of prostate cancer cells by a novel dual inhibitorRole of Bruton's tyrosine kinase inhibitors in HIV-1-infected cellsMicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesIbrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth.A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.Biological therapy doublets: pairing rituximab with interferon, lenalidomide, and other biological agents in patients with follicular lymphoma.Diffuse large B cell lymphoma: molecular targeted therapy.Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype.BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Ibrutinib-A double-edge sword in cancer and autoimmune disorders.Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
P2860
Q21131224-79C09740-B64A-4931-9AF8-FED674DD5CE3Q28269136-DFEFDB84-BA6E-496E-9367-4E4E05512F49Q30661625-C983B80F-C6E3-48EF-BCFB-DD3F39E195FAQ35612194-54611456-2CE4-4BA7-BD6E-541BDD801E18Q36602853-18D1F875-9664-43DC-95D2-5AB07D5C68ADQ36870866-09FC75B0-AB37-4420-902E-C17DFEA941E3Q37144044-7650D705-34DD-4AD8-88F2-25A18B74A02AQ37222219-1D345E08-631C-4A9C-84A6-0AA43A02A33CQ38034939-8673D778-158E-4EEF-BD92-67E896B34655Q38053983-167ABE79-EE95-47BB-8E19-A7B61C6D708AQ38062922-EC1B0221-7840-4051-9779-C5AAB79A214EQ38101590-9B540E30-4C1D-4D06-BB3B-285ECE3D1E87Q38101683-E1CA97AE-E4E6-46FA-BBD9-C871464AB148Q38161760-72946395-0390-4E9C-A208-0BBF487F08BDQ38171390-5416F801-5116-4543-BFD1-468CA6B947C7Q38554422-2280E53B-B60C-4EF4-8784-49139B014C03Q38585329-6AB487D3-7514-49FE-A5A7-02E7DD076940Q47719484-8BC099B6-4B61-4904-9BBF-E40EA5484167Q47977912-09DE9447-0F9F-45B3-A287-D34B55C0B3BDQ49731233-63464B0D-C1D9-44EB-93A7-3391684A4054
P2860
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@en
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@nl
type
label
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@en
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@nl
prefLabel
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@en
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@nl
P2860
P1476
PCI-32765: a novel Bruton's ty ...... ment of lymphoid malignancies.
@en
P2093
Eric S Winer
Randall R Ingham
P2860
P304
P356
10.1517/13543784.2012.656199
P407
P577
2012-02-03T00:00:00Z